AbCellera and Canada to invest $500M+ to boost antibody manufacturing and research
AbCellera, a Vancouver-based antibody manufacturer, received an investment from the government of Canada and the province of British Columbia.
The investment will total CA$701 million ($515.9 million) over the next eight years, with the funding going toward building new infrastructure to develop antibody-based medicines. This includes a site to develop and manufacture antibody medicines through the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.